Product image of Ondansetrom Aurovitas (Ondansetron) supplied by GNH India

Ondansetrom Aurovitas

Active Ingredient:
Ondansetron
Origin:
EU

Ondansetrom Aurovitas (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Aurovitas, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery in adult and paediatric patients.

GNH India supplies Ondansetrom Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings.

  • Chemotherapy‑induced nausea and vomiting (CINV): helps prevent and treat acute and delayed episodes.
  • Radiotherapy‑induced nausea and vomiting (RINV): reduces the frequency and severity of symptoms.
  • Post‑operative nausea and vomiting (PONV): decreases incidence after general anaesthesia.
  • Pregnancy‑associated nausea (hyperemesis gravidarum): used when benefits outweigh risks, under specialist supervision.

How It Works

  • Ondansetron selectively blocks the 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting serotonin binding, it prevents the neural signaling that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapy, radiotherapy, surgery and other triggers.

Side Effects

Side‑effect profiles reflect the drug’s pharmacology and are generally mild to moderate.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel motility.
  • Diarrhoea: occasional loose stools.
  • Fatigue: feeling of tiredness.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • QT‑interval prolongation: may predispose to cardiac arrhythmias.
  • Severe hypersensitivity: rash, angio‑edema or anaphylaxis.
  • Serotonin syndrome: rare when combined with other serotonergic agents.
  • Hepatic dysfunction: elevated liver enzymes in susceptible individuals.

Precautions & Warnings

When prescribing ondansetron, clinicians should consider patient‑specific factors and monitor for adverse reactions.

  • Cardiac risk assessment: evaluate baseline ECG in patients with known QT prolongation.
  • Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use.
  • Drug‑interaction review: avoid concurrent use with other QT‑prolonging agents.
  • Pregnancy and lactation: use only if clearly needed, after risk‑benefit analysis.
  • Renal/hepatic impairment: dose adjustment may be required in severe dysfunction.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Avoid Interactions

Ondansetron may interact with several drug classes, altering cardiac rhythm or serotonergic activity.

Major Interactions (Avoid)

  • Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of torsades de pointes.
  • Apomorphine: can cause profound hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely)

  • Antidepressants (SSRIs, SNRIs, MAOIs): potential for serotonin syndrome.
  • Antifungal azoles (ketoconazole, fluconazole): may raise ondansetron plasma levels.
  • Macrolide antibiotics (erythromycin, clarithromycin): modest increase in QT interval.
  • Calcium channel blockers (diltiazem, verapamil): may enhance QT prolongation.
  • Digoxin: slight increase in serum concentration.

Frequently Asked Questions

Ondansetrom Aurovitas contains ondansetron, an anti‑emetic that is used to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, surgery and, in some cases, severe pregnancy‑related nausea. It is prescribed for both adult and paediatric patients under medical supervision.

Ondansetron blocks serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. By preventing serotonin from activating these receptors, the drug interrupts the neural pathway that triggers the vomiting reflex, thereby reducing nausea and vomiting.

The dose of ondansetron is individualized by the prescribing clinician based on the indication, patient age, weight and renal or hepatic function. Healthcare professionals determine the appropriate strength, frequency and duration of therapy for each patient.

Ondansetron is classified as a pregnancy category B medication in the EU, meaning animal studies have not shown risk but adequate human studies are lacking. It may be used during pregnancy only when the potential benefit justifies the risk, and breastfeeding mothers should consult their physician because small amounts can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ondansetron is a selective 5‑HT3 antagonist, offering a targeted mechanism compared with dopamine antagonists (e.g., metoclopramide) or antihistamines (e.g., diphenhydramine). It generally provides effective control of chemotherapy‑induced nausea with a lower risk of extrapyramidal side effects, though QT‑interval prolongation requires cardiac monitoring.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency.

Ondansetrom Aurovitas is supplied as oral tablets that are swallowed whole with water. The timing of administration depends on the clinical situation—often given 30 minutes before chemotherapy, radiotherapy or surgery, and may be continued for several days as directed by the prescriber.

The most serious risks include QT‑interval prolongation, which can lead to potentially life‑threatening cardiac arrhythmias, and rare severe hypersensitivity reactions such as anaphylaxis. Patients with existing cardiac conduction abnormalities or electrolyte disturbances should be monitored closely.

Ondansetron should be avoided in patients with known hypersensitivity to the drug or any of its excipients, and in those taking apomorphine. Caution is advised for individuals with congenital long‑QT syndrome, uncontrolled electrolyte imbalances, or those concurrently using other QT‑prolonging medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT